Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Melanoma-associated antigen (MAGE family) (MAGE)
- Target
- MAGE
- Molecular classification
- Cancer/testis antigen (CT antigen), Tumor antigen, Tumor-associated antigen, Protein family (subgroups: MAGE-A, MAGE-B, MAGE-C, etc.)
01
Overview
Melanoma-associated antigens comprise a large protein family, most notably the MAGE family, which are highly expressed in malignant tumors such as melanoma and various epithelial cancers, but are generally absent from normal adult tissues except the testis and placenta. They are classified as cancer/testis antigens and are recognized by cytotoxic T cells, making them attractive as targets for cancer immunotherapy. Multiple subfamilies exist (notably MAGE-A, MAGE-B, MAGE-C), each containing several genes with some functional redundancy and variation. MAGE proteins are under investigation as therapeutic targets and as biomarkers for cancer diagnostics and prognostics. Currently, there are no drugs directly inhibiting these antigens, but immunotherapeutic approaches, including vaccines and cellular therapies, are in development.
- Other names
- Melanoma antigen geneMAGE familyCancer/testis antigenCT antigen
02
Mechanism of action
Cancer immunotherapy agents leverage immune recognition of MAGE antigens—mechanisms include vaccine-induced cellular immune response and adoptive T cell therapy using T cells engineered to recognize MAGE epitopes
03
Biological functions
Immune response (recognized by cytotoxic T lymphocytes as antigens)Regulation of apoptosisPromotion of cancer cell proliferation and survivalCell cycle regulationOther (exact biological functions for all MAGE family members remain incompletely characterized)
04
Disease associations
Cancer (expressed in melanoma, bladder, lung, esophageal, and other cancers)Other (as target antigens for immunotherapy)
05
Safety considerations
Off-tumor toxicity: while MAGE antigens are usually restricted to tumors/testis, some normal tissue expression risks on-target, off-tumor effects in immunotherapyImmunological risk: potential for autoimmunity if antigens cross-react with normal tissuesLimited efficacy: immune evasion and antigen loss variants in tumors may limit response
06
Interacting drugs
No approved small-molecule drugs directly target MAGE proteins yet
1 more in the full profile.
07
Biomarkers
Expression of MAGE-A family members used as diagnostic/prognostic biomarkers in several cancers (e.g., bladder, melanoma)
Beyond the preview
Go deeper on Melanoma-associated antigen (MAGE family) (MAGE).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Melanoma-associated antigen (MAGE family) (MAGE).